美股异动丨Viking Therapeutics盘前大涨超16%，公布口服减肥药后期测试计划

Core Viewpoint - Viking Therapeutics plans to advance its experimental weight loss drug VK2735 into late-stage research in the third quarter of this year, following positive mid-stage study results indicating effective weight maintenance through a low-dose oral treatment strategy [1] Group 1: Company Developments - Viking Therapeutics' stock rose by 16.3% to $33.2 in pre-market trading [1] - The company emphasizes that the regulatory pathway for VK2735 has advantages over its injectable weight loss drug project, potentially shortening trial duration and reducing trial scale [1] Group 2: Industry Insights - The positive mid-stage research results for VK2735 highlight a growing interest in oral weight loss treatments within the pharmaceutical industry [1]